Participant flow

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia · Source last updated 2016-07-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Drug: pomalidomide Taken orally once a day Drug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15 Drug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15 pomalidomide: Taken orally once a day dexamethasone: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15 rituximab: Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15

   id

   FG000

   title

   Pomalidomide, Dexamethasone, Rituximab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         3

      type

      Adverse Event

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         7

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         4

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

A total of 7 participants were recruited at the DFCI medical clinic between 9/22/2010 and 4/3/2012.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice